DK1268766T3 - Forbedringer af ribosom-display - Google Patents

Forbedringer af ribosom-display

Info

Publication number: DK1268766T3
Authority: DK; Denmark
Prior art keywords: specific binding; oxidised; optionally; ratio; combination
Prior art date: 2000-03-31

Application number

DK01914058T

Other languages

Danish (da)

English (en)

Inventor

Jane Osbourn

Thor Holet

Original Assignee

Cambridge Antibody Tech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-31

Filing date

2001-03-26

Publication date

2006-04-10

2001-03-26 Application filed by Cambridge Antibody Tech filed Critical Cambridge Antibody Tech

2006-04-10 Application granted granted Critical

2006-04-10 Publication of DK1268766T3 publication Critical patent/DK1268766T3/da

Links

238000002702 ribosome display Methods 0.000 title abstract 2
230000009870 specific binding Effects 0.000 abstract 3
108010024636 Glutathione Proteins 0.000 abstract 2
102000016227 Protein disulphide isomerases Human genes 0.000 abstract 2
108050004742 Protein disulphide isomerases Proteins 0.000 abstract 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 2
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 abstract 2
108090000565 Capsid Proteins Proteins 0.000 abstract 1
BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 abstract 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
229960002897 heparin Drugs 0.000 abstract 1
229920000669 heparin Polymers 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000010348 incorporation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Crystallography & Structural Chemistry (AREA)
Plant Pathology (AREA)
Bioinformatics & Computational Biology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Ink Jet Recording Methods And Recording Media Thereof (AREA)

DK01914058T 2000-03-31 2001-03-26 Forbedringer af ribosom-display DK1268766T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US19380200P	2000-03-31	2000-03-31

Publications (1)

Publication Number	Publication Date
DK1268766T3 true DK1268766T3 (da)	2006-04-10

Family

ID=22715061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01914058T DK1268766T3 (da)	2000-03-31	2001-03-26	Forbedringer af ribosom-display

Country Status (11)

Country	Link
US (2)	US7074557B2 (fr)
EP (1)	EP1268766B1 (fr)
JP (1)	JP2003529369A (fr)
AT (1)	ATE311444T1 (fr)
AU (2)	AU3944401A (fr)
CA (1)	CA2402452A1 (fr)
DE (1)	DE60115405T2 (fr)
DK (1)	DK1268766T3 (fr)
ES (1)	ES2253358T3 (fr)
GB (1)	GB2365429B (fr)
WO (1)	WO2001075097A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4060892B2 (ja)	1997-05-28	2008-03-12	ディサーナリミテッド	タンパク質のｉｎｖｉｔｒｏディスプレイ及び進化のための選択粒子としてのリボソーム複合体
EP1664343B1 (fr) *	2003-09-09	2014-05-07	Integrigen, Inc.	Procedes et compositions de generation de genes d'anticorps humains de lignee germinale
US20070111237A1 (en) *	2005-09-14	2007-05-17	Maurizio Zanetti	Process for identifying antigenized antibodies using ribosome cell free expression system
US7749957B2 (en)	2006-04-06	2010-07-06	E.I. Du Pont De Nemours And Company	Clay-binding peptides and methods of use
US9879252B2 (en)	2007-06-13	2018-01-30	Cornell Research Foundation, Inc.	Protein discovery using intracellular ribosome display
WO2009018438A1 (fr) *	2007-07-31	2009-02-05	Cornell Research Foundation, Inc.	Découverte de protéine utilisant un affichage de ribosome intracellulaire
US7951559B2 (en) *	2007-07-25	2011-05-31	E.I. Du Pont De Nemours And Company	Recombinant peptide production using a cross-linkable solubility tag
US7678883B2 (en)	2007-07-25	2010-03-16	E.I. Du Pont De Nemours And Company	Solubility tags for the expression and purification of bioactive peptides
US7829311B2 (en)	2007-07-25	2010-11-09	E.I. Du Pont De Nemours And Company	Ketosteroid isomerase inclusion body tag engineered to be acid-resistant by replacing aspartates with glutamate
US7794963B2 (en)	2007-11-02	2010-09-14	E.I. Du Pont De Nemours And Company	Use of tetracysteine tags in fluorescence-activated cell sorting analysis of prokaryotic cells producing peptides or proteins
GB0806562D0 (en)	2008-04-10	2008-05-14	Fermentas Uab	Production of nucleic acid
KR20110036638A (ko)	2008-07-25	2011-04-07	리차드 더블유. 와그너	단백질 스크리닝 방법
WO2010036860A2 (fr) *	2008-09-26	2010-04-01	Wyeth Llc	Systèmes de vecteurs de présentation compatibles
US8313942B2 (en) *	2008-09-26	2012-11-20	Wyeth Llc	Compatible display vector systems
CA2737035A1 (fr) *	2008-09-30	2010-04-08	Abbott Laboratories	Procede ameliore d'affichage d'arn
US20100158846A1 (en) *	2008-12-18	2010-06-24	E. I. Du Pont De Nemours And Company	Hair-binding peptides
US8287845B2 (en) *	2008-12-18	2012-10-16	E I Du Pont De Nemours And Company	Hair-binding peptides
US20100158837A1 (en)	2008-12-18	2010-06-24	E. I. Du Pont De Nemours And Company	Iron oxide-binding peptides
US20100158822A1 (en) *	2008-12-18	2010-06-24	E .I. Du Pont De Nemours And Company	Peptides that bind to silica-coated particles
US8481678B2 (en)	2009-03-30	2013-07-09	E I Du Pont De Nemours And Company	Peptide-based tooth whitening reagents
EP2414045A2 (fr) *	2009-03-30	2012-02-08	Johnson & Johnson	Systèmes à base de peptide pour l'administration d'agents cosmétiques
EP2546342A4 (fr)	2010-03-11	2013-12-04	Riken	Méthode de sélection d'une séquence polypeptidique, peptide de fixation d'un composé contenant un oxyde de métal ou du silicium et leur utilisation
BR112013015508B1 (pt)	2010-12-20	2022-04-05	Medimmune Limited	Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
DE102010056289A1 (de)	2010-12-24	2012-06-28	Geneart Ag	Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
JP5948673B2 (ja)	2011-03-10	2016-07-06	ジーンフロンティア株式会社	リポ多糖混入量を低減した蛋白質合成用組成物、該組成物を用いた蛋白質製造方法
WO2012161227A1 (fr)	2011-05-23	2012-11-29	独立行政法人理化学研究所	Construction d'acide nucléique, complexe acide nucléique-protéine et leur utilisation
WO2014060444A1 (fr)	2012-10-15	2014-04-24	Medimmune Limited	Anticorps anti-bêta-amyloïde
EP2989202B1 (fr)	2013-04-25	2019-04-10	Sutro Biopharma, Inc.	L'utilisation de la lambda-gam protéine dans la technologie de ribosome display
US20160069897A1 (en) *	2013-04-25	2016-03-10	Suthro Biopharma, Inc.	Selection of fab fragments using ribosomal display technology
US10011830B2 (en) *	2013-05-19	2018-07-03	The Board of Trustee of theLeland Stanford junior University	Devices and methods for display of encoded peptides, polypeptides, and proteins on DNA
WO2015048391A1 (fr)	2013-09-27	2015-04-02	The Board Of Trustees Of The University Of Illinois	Procédé et nécessaire permettant de générer des agents de liaison à haute affinité
EP3102245B1 (fr)	2014-02-05	2021-09-08	Molecular Templates, Inc.	Procédés de criblage, de sélection et d'identification de polypeptides de recombinaison cytotoxiques fondés sur une diminution provisoire de la ribotoxicité
CA2985816A1 (fr)	2015-05-15	2016-11-24	The General Hospital Corporation	Anticorps antagonistes de la superfamille du recepteur du facteur de necrose anti-tumoral
EP3380613B1 (fr)	2015-11-23	2022-10-26	The Regents of the University of California	Suivi et manipulation d'arn cellulaire par distribution nucléaire de crispr/cas9
WO2018208998A1 (fr)	2017-05-10	2018-11-15	The Regents Of The University Of California	Édition dirigée d'arn cellulaire par administration nucléaire de crispr/cas9
WO2019204828A1 (fr) *	2018-04-20	2019-10-24	The Regents Of The University Of California	Protéines de fusion et acides ribonucléiques de fusion pour le suivi et la manipulation d'arn cellulaire
US11174479B2 (en)	2018-08-13	2021-11-16	The Board Of Trustees Of The Leland Stanford Junior University	Devices and methods for display of encoded peptides, PolyPeptides, and proteins on DNA
EP3853252A1 (fr)	2018-09-18	2021-07-28	Merrimack Pharmaceuticals, Inc.	Anticorps anti-tnfr2 et leurs utilisations
EP3930846A1 (fr)	2019-03-01	2022-01-05	Merrimack Pharmaceuticals, Inc.	Anticorps anti-tnfr2 et leurs utilisations
WO2022167396A1 (fr)	2021-02-02	2022-08-11	Biocopy Gmbh	Procédé d'identification des mutations d'agents pathogènes émergents permettant l'entrée dans les cellules hôtes et l'évasion immunitaire

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69032483T2 (de)	1989-10-05	1998-11-26	Optein, Inc., Seattle, Wash.	Zellfreie synthese und isolierung von genen und polypeptiden
WO1994006920A1 (fr)	1992-09-22	1994-03-31	Medical Research Council	Virus recombines presentant un polypeptide non-viral sur leur surface externe
US5443969A (en)	1992-10-29	1995-08-22	Rutgers University	RNA packaging system
WO1995011922A1 (fr)	1993-10-29	1995-05-04	Affymax Technologies N.V.	Banques de presentation de peptides et d'anticorps in vitro
US5939262A (en)	1996-07-03	1999-08-17	Ambion, Inc.	Ribonuclease resistant RNA preparation and utilization
US5677124A (en)	1996-07-03	1997-10-14	Ambion, Inc.	Ribonuclease resistant viral RNA standards
JP4086325B2 (ja) *	1997-04-23	2008-05-14	プリュックテュン，アンドレアス	標的分子と相互作用する（ポリ）ペプチドをコードする核酸分子の同定方法
JP4060892B2 (ja)	1997-05-28	2008-03-12	ディサーナリミテッド	タンパク質のｉｎｖｉｔｒｏディスプレイ及び進化のための選択粒子としてのリボソーム複合体
WO1999011777A1 (fr) *	1997-09-03	1999-03-11	Biovation Limited	Procedes d'analyse de proteines
US6562622B1 (en)	1998-05-08	2003-05-13	Diatech Pty, Ltd	Continuous in vitro evolution

2001
- 2001-03-26 DE DE60115405T patent/DE60115405T2/de not_active Expired - Lifetime
- 2001-03-26 AU AU3944401A patent/AU3944401A/xx active Pending
- 2001-03-26 GB GB0107543A patent/GB2365429B/en not_active Expired - Lifetime
- 2001-03-26 ES ES01914058T patent/ES2253358T3/es not_active Expired - Lifetime
- 2001-03-26 JP JP2001572971A patent/JP2003529369A/ja active Pending
- 2001-03-26 AT AT01914058T patent/ATE311444T1/de active
- 2001-03-26 US US09/817,661 patent/US7074557B2/en not_active Expired - Lifetime
- 2001-03-26 EP EP01914058A patent/EP1268766B1/fr not_active Expired - Lifetime
- 2001-03-26 DK DK01914058T patent/DK1268766T3/da active
- 2001-03-26 AU AU2001239444A patent/AU2001239444B2/en not_active Expired
- 2001-03-26 CA CA002402452A patent/CA2402452A1/fr not_active Abandoned
- 2001-03-26 WO PCT/GB2001/001319 patent/WO2001075097A2/fr active IP Right Grant
2006
- 2006-02-23 US US11/362,309 patent/US20060177862A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1268766B1 (fr)	2005-11-30
AU2001239444B2 (en)	2004-10-07
CA2402452A1 (fr)	2001-10-11
WO2001075097A3 (fr)	2002-01-03
JP2003529369A (ja)	2003-10-07
US7074557B2 (en)	2006-07-11
GB2365429B (en)	2002-07-24
US20060177862A1 (en)	2006-08-10
US20020076692A1 (en)	2002-06-20
WO2001075097A2 (fr)	2001-10-11
DE60115405D1 (de)	2006-01-05
DE60115405T2 (de)	2006-08-03
AU3944401A (en)	2001-10-15
GB2365429A (en)	2002-02-20
ATE311444T1 (de)	2005-12-15
GB0107543D0 (en)	2001-05-16
ES2253358T3 (es)	2006-06-01
EP1268766A2 (fr)	2003-01-02

Publication	Publication Date	Title
DK1268766T3 (da)	2006-04-10	Forbedringer af ribosom-display
CY1119291T1 (el)	2018-02-14	Πολυσθενη αντισωματα και χρησεις για αυτα
CY2019029I1 (el)	2020-05-29	Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY2014038I1 (el)	2015-12-09	Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY2018010I2 (el)	2018-09-05	Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE384792T1 (de)	2008-02-15	Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
EP2221317A3 (fr)	2011-07-27	Single domain anticorps (dAb) conjugés à PEG
BR0314093A (pt)	2005-07-05	Proteìnas de fusão de transferrina modificada-anticorpo
CY1110877T1 (el)	2015-06-10	Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
BR0212256A (pt)	2004-08-31	Proteìnas de fusão de transferrina modificadas
WO2003068201A3 (fr)	2003-12-04	Anticorps presentant une specifite de type recepteur des lymphocytes t, une affinite encore superieure, et utilisation de celui-ci dans la detection et le traitement du cancer, d'infections virales et de maladies auto-immunes
NO20033548D0 (no)	2003-08-11	Modifiserte proteiner, designer toksiner og fremgangsmåter for fremstillingav disse
DK1255826T3 (da)	2006-01-30	Automatisering af proteindesign for proteinbiblioteker
DK0922102T3 (da)	2010-08-16	Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
DE60044420D1 (de)	2010-07-01	Enzym-Protein-Komplex
WO2004083245A3 (fr)	2004-11-04	Agent
AU2002365269A1 (en)	2003-07-24	Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
BRPI0507019A (pt)	2007-06-05	composição, uso de anticorpo, anticorpo, uso de msrv/herv-w env-su
WO2003009887A3 (fr)	2003-09-18	Colonnes d'immuno-absorption pour la soustraction d'anticorps du sang avec des techniques de filtration du plasma selectives
WO2003014728A1 (fr)	2003-02-20	Medicaments contre l'hepatite c